Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Dan ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(178)
•••
Comment by Layth1990on Feb 25, 2021 4:51pm
157 Views
Post# 32665535

RE:RE:RE:Dan ...

RE:RE:RE:Dan ...

Ofcourse they will rate 14.5cad/share because everyone who invested are banging their heads against the wall. 

don't get me wrong! My average is really low and i'm long on ate. I think it is not fair for the new investors to be set this way. Put youtself in their shoes, -25% at least in couple of days! 

i'm not really a fan of dan and i believe things would be much better without him, i do believe in the science though. He took our best news which is the nuance deal and burnt things down to hell. I don't think he is a great ceo. Great ceos create uptrend stock value, gain investors trust, move things fast while managing the corporate.

this stock will not progress if things will continue this way. You have to progress in  both the corporate and Stock value. Corporate is just worthless without its investors.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities